Anacapa Technologies Revenue and Competitors
Estimated Revenue & Valuation
- Anacapa Technologies's estimated annual revenue is currently $5.3M per year.
- Anacapa Technologies's estimated revenue per employee is $155,000
Employee Data
- Anacapa Technologies has 34 Employees.
- Anacapa Technologies grew their employee count by -3% last year.
Anacapa Technologies's People
Name | Title | Email/Phone |
---|---|---|
1 | Regional Sales Representative | Reveal Email/Phone |
Anacapa Technologies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Anacapa Technologies?
Anacapa Technologies, Inc. is a market leader and innovator in the formulation of broad spectrum antimicrobial wound care products. Anasept® Antimicrobial Skin & Wound Cleanser and Gel is a powerful board-spectrum, topical antimicrobial that is long-acting, crystal clear and highly-viscous, available in a tube as a hydrogel or as a liquid in spray and pour bottles. What will Anasept® treat? • Anasept® Antimicrobial Skin & Wound Gel is a long-acting thick hydrogel indicated for the management of partial to full thickness wounds, pressure ulcers, diabetic foot ulcers, surgical incisions, first and second degree burns, donor, and graft sites. • Anasept® Antimicrobial Skin & Wound Cleanser (liquid & spray) is used for general antiseptic site preparation for central line, graft-fistula cannulation and wound cleansing and debridement. • There is no known resistance to Anasept®. Anasept® quickly kills infection causing bacteria (including MRSA, VRE, C. difficile), C. difficile spores, pathogenic fungi, Hepatitis and HIV. • Anasept® is unmatched in eliminating the foulest orders • Anasept® is also known to assist with the effective debridement of necrotic slough and bio-debris due to its unique molecular action.
keywords:N/AN/A
Total Funding
34
Number of Employees
$5.3M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7M | 35 | 6% | N/A |
#2 | $10.3M | 40 | 8% | N/A |
#3 | $10M | 43 | 54% | N/A |
#4 | $10.2M | 44 | -4% | N/A |
#5 | $8.5M | 47 | 4% | N/A |